Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Empagliflozin/Metformin
Drug: Empagliflozin
Drug: Metformin

First Posted Date: 2013-03-15

Last Posted Date: 2015-07-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT01811953

Locations: 🇩🇪
1276.8.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Preference Tiotropium Respimat Study in COPD

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2013-03-13

Last Posted Date: 2015-03-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 150

Registration Number: NCT01810692

Locations: 🇪🇸
Boehringer Ingelheim Investigational Site 13, A Coruña, Spain
🇪🇸
Boehringer Ingelheim Investigational Site 5, Barcelona, Spain
🇪🇸
Boehringer Ingelheim Investigational Site 8, Barcelona, Spain

and more 12 locations

Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: single dose of 2 mcg
Drug: single dose of 5 mcg
Drug: single dose of 10 mcg
Drug: single dose of 20 mcg
Drug: single dose of 40 mcg
Drug: single dose of placebo

First Posted Date: 2013-03-12

Last Posted Date: 2014-06-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01809262

Locations: 🇳🇱
1222.3.1 Atrium medisch centrum, Heerlen, Netherlands

Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Itraconazole
Drug: Atorvastatin
Drug: Faldaprevir
Drug: Rosuvastatin

First Posted Date: 2013-02-21

Last Posted Date: 2015-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 51

Registration Number: NCT01795937

Locations: 🇩🇪
1220.61.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Linagliptin 5mg

First Posted Date: 2013-02-15

Last Posted Date: 2017-03-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 360

Registration Number: NCT01792518

Locations: 🇻🇳
Boehringer Ingelheim Investigational Site, Ho Chi Minh City, Vietnam

Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 113608
Drug: Ketoconazole
Drug: Voriconazole

First Posted Date: 2013-02-08

Last Posted Date: 2017-03-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 20

Registration Number: NCT01787032

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Ingelheim, Germany

Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Raltegravir
Drug: Faldaprevir

First Posted Date: 2013-02-07

Last Posted Date: 2015-08-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT01785160

Locations: 🇩🇪
1220.65.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BI 10773
Drug: BI 10773 / BI 1356 Placebo
Drug: BI 10773 / BI 1356
Drug: BI 10773 Placebo

First Posted Date: 2013-01-29

Last Posted Date: 2016-04-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 708

Registration Number: NCT01778049

Locations: 🇵🇹
1275.10.35104 Boehringer Ingelheim Investigational Site, Cantanhede, Portugal
🇵🇹
1275.10.35112 Boehringer Ingelheim Investigational Site, Porto, Portugal
🇺🇦
1275.10.38002 Boehringer Ingelheim Investigational Site, Kiev, Ukraine

and more 111 locations

SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Pradaxa (Dabigatran etexilate mesilate)

First Posted Date: 2013-01-24

Last Posted Date: 2019-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3182

Registration Number: NCT01774370

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

Phase 2

Withdrawn

Conditions: Venous Thromboembolism

Interventions: Drug: dabigatran etexilate

First Posted Date: 2013-01-23

Last Posted Date: 2015-10-26

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT01773174

Locations: 🇺🇸
1160.145.00007 Boehringer Ingelheim Investigational Site, Newark, New Jersey, United States
🇺🇸
1160.145.00010 Boehringer Ingelheim Investigational Site, Sacramento, California, United States
🇺🇸
1160.145.00009 Boehringer Ingelheim Investigational Site, Louisville, Kentucky, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy